New diagnostic modalities in soft tissue sarcoma.

Abstract

Molecular and cytogenetic analysis of soft tissue sarcoma has provided a vast amount of new genetic information over the past 10 years. Recent advances in genetic technology, such as fluorescence in situ hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR), and positional cloning techniques have greatly increased the rate of new discoveries and soon may bring cytogenetic and molecular analysis to standard pathology laboratories. Karotypic analysis of soft tissue tumors have demonstrated specific cytogenetic aberrations which have proved to be extremely useful diagnostically and have solidified and improved soft tissue tumor classification systems. Objective and reproducible prognostication in soft tissue sarcoma remains problematic. Presently, the grade and size of the sarcoma are the most important factors used to estimate risk of relapse and overall survival. Assigning a pathologic grade to an individual sarcoma as a means of predicting clinical behavior is often difficult with a 40% discordance rate even between expert sarcoma pathologists. There is mounting evidence that the composition of membrane phospholipid in tumor tissue is an important indicator of a tumor's cellularity, proliferative capacity, and differentiation state. However, there is a lack of information on the biochemical determinants of sarcoma proliferation and differentiation. To address these problems, novel quantitative ex vivo nuclear magnetic resonance (NMR) methods have been applied to determine the biochemical changes in tissue lipid for soft tissue sarcoma. The biochemical changes in tissue lipid have been found to correlate with sarcoma cellularity, growth rate, and differentiation. Continued prospective NMR analysis of tissue lipid biochemistry in soft tissue tumors will permit the development of a clinically relevant biochemical system of prognostic determinants for soft tissue sarcoma in the future.